Krop said that one of the unique features of the study that will appeal to the first population of -positive breast cancer-positive breast cancer, whose disease has progressed despite treatment with all of the FDA – approved drugs for this disease .

In addition to the current study, T-DM1 is in larger Phase 3 studies compared the effectiveness of of the testing combination of different therapies. Bill Schaller Dana-Farber Cancer Institute:.Pre-planned analysis iron chelation study demonstrates once-daily Exjade reducing toxic iron levels patients with myelodysplastic syndromes.